Early onset pancreatic cancer: a controlled trial.
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) represents the fourth cause of death in cancer with a 5-year survival rate of less than 1-2%. Early onset pancreatic cancer (EOPC), i.e. patients below 50 years of age, is infrequently described. The present study aimed to determine the epidemiology, demographic incidence and prognosis of EOPC and to identify the characteristics that might distinguish EOPC.


METHODS
576 consecutive patients with PDAC diagnosed from January 1993 to December 2008 at the University Hospital of Lund, Sweden. 65 different parameters were compared with a historic cohort of pancreatic cancer patients as well as with matched controls.


RESULTS
33 patients (5.7%) with PDAC were 50 years or younger. The overall survival was 170 days compared to 240 days for matched controls (p=n.s.). Patients with EOPC were diagnosed at a significantly more advanced stage, i.e. distant metastasis, (52%) as compared to matched controls (30%; p=0.04). EOPC-patients received more treatment than the compared PDAC-cohort.


CONCLUSIONS
EOPC constituted 5.7 % of all PDAC, presenting at an advanced stage with frequent metastases and poor survival. The role of genetic alterations and the potential influence of environmental factors for EOPC are to be further investigated.
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital Lund and Lund University, Sweden.
Bobby
B
Tingstedt
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital Lund and Lund University, Sweden.
Carl
C
Weitkämper
Department of Surgery, Clinical Sciences Lund, Skåne University Hospital Lund and Lund University, Sweden.
Roland
R
Andersson
early onset; matched controls; outcome; pancreatic cancer